Dr. Jonas Bergquist, OMF Chief Medical Officer, Talks OMF's First Clinical Trial
Вставка
- Опубліковано 9 лип 2024
- Today Dr. Jonas Bergquist sits down to chat about OMF's first clinical trial, The Life Improvement Trial (LIFT). This clinical treatment trial is a major step towards understanding and treating Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Long COVID more effectively.
What is The LIFT?
Conducted under the direction of David Systrom, MD, Director of our Harvard Collaboration and Jonas Bergquist, MD, PhD, OMF’s Chief Medical Officer and Director of the Uppsala University Collaboration, The LIFT is a randomized, double-blind placebo trial that will investigate two particular drugs: Pyridostigmine (commonly known as Mestinon) and low-dose naltrexone (LDN) separately and together as a combination.
Dr. Bergquist speaks more on trial setup, expected timelines of the trial, why this is an important first step, and more.
Very emotional about the first ever proper trial for me/CFS treatment. Thank you so much OMF, you are fantastic.
Wow, i have been ill for more than 35 years ... I hope I will live long enough to benefit from the results ...
Yes, I'm about 3 decades in with a typical story, sold my business, lost everything and I'm 66.. Let's hope this is helpful. Blessings.
This is very exciting -- thank you researchers and participants!!
Yay I love that it's going to use the funcap thing, I remember hearing about it on the ME conference. This is literally by far the best designed ME study I've ever seen, in terms of what it tracks - so many real functional, hard data and biomedical data changes, and a three month long trial.... Amazing! We're going to learn so much from this. I couldn't be more excited (and not just because it's the possibility of a treatment either, the whole package is very exciting)
No doubt this trail is going to provide a great amount of information one way or an other!
Really hope there's something soon for us to take to make this horrible illness better. 😢
thank you :) updates are so appreciated
Praying for your success. Thank you infinitely!
Thanks so much for the update, it is good to hear about the experimental design and all the different objective measurements that will be taken. I also enjoy listening to your accent :)
I have some data points to share but don't know where to send them for OMF. I just started taking pyridostigmine a month ago. I started the LDN more than a year ago. For the first time in over 6 years, a medication is making a significant and noticable difference on my length of upright activity time. I have just a few data points from tests early on that might support the itaconate shunt hypothesis as well as the beneficial impacts of these two meds. If anyone at OMF reads this and is interested in some potentially supporting data, please let me know how best to submit the little bit of info I have. Thank you for your amazing work. Even though these medications have been tried for years, it will be wonderful to finally have an official and properly designed, run, and powered trial. It brings hope. Please keep up the great work. We will try to support your efforts the best we can.
Exciting!
Well done!
Universe blesses you! .Thanks of a ME patient from Spain. Good luck with Clinical Trial. I am taking LDN and helps me and maybe I will try Mestinon soon!
I suspect the LDN is treating the symptoms of the microglia, not necessarily the underlying cause of ME/CFSs (though it could reduce positive feedback loop of pro-inflammation).
would be cool to find & test a CAD/ JAK STAT inhibitor!
Any idea which ones? I want to experiment
Really hoping for good results and some answers. Been ill for almost 35 years now.
Will there be any follow-up with subjects beyond the initial 3 months? Three months maybe be long for a clinical trial, but it's not very long for a disease in which symptoms frequently wax and wane over time.
Exciting news - just wondering what the dose of the drugs are being trialled and what staggered timing is being used for the combination trial?
A cause and a cure are the only answers.
Lastly very interested to know if any interim indications on outcomes will be shared after each 3 month cohort?
Update? And why on earth aren't you testing CAD / JAK STAT inhibitors??
Also interested in current view on improvement with the trial medications - after 3 months is improvement likely to plateau or continue to increase?
lets see if the side-effects of the medicines used in each treatment group are the same, otherwise its not blinded
It would be as blinded as any clinical trial of any medication with potential side-effects ever is.
But in fact, the common side-effects of the two drugs are quite similar.
But LDN has been tested with our illness for many, many years. Seems you're late to the party.
Nothing close to this. Participants is higher than any trial, longevity is 3 months, what they're measuring is more accurate, 4 groups with different drugs etc. Other trials have been prelim studies. This is comprehensive.
There have been no clinical trials of LDN for ME/cfs. The only published research I could find were a couple of papers theorizing about why and how it might work, and a clinical case study of two patients.
The rest of the information we have is anecdotal.
"...{Mestinon) and low-dose naltrexone (LDN) separately and together as a combination." Synergistic effect it sounds like. Also, not all, but some patients are helped with LDN from what I have read through patient testimony. Let's hope.